December 20, 2014 9:54 PM ET

Pharmaceuticals

Company Overview of Boehringer Ingelheim Corporation

Company Overview

Boehringer Ingelheim Corporation, through its subsidiaries, discovers, develops, manufactures, and markets human and animal health care products in the United States. It offers cardiovascular, respiratory, HIV, immunology, central nervous system, and urology products; active pharmaceutical ingredients; oral liquids, tablets, and capsules; and products for the treatment of diseases in dogs, cats, horses, cattle, and swine. The company also provides over-the-counter health care products, including Dulcolax, which is used for occasional constipation and irregularity problems; Zantac that is used for the prevention and relief of heartburn; and Mirapex ER, a tablet for the signs and symptoms of i...

900 Ridgebury Road

P.O. Box 368

Ridgefield, CT 06877-0368

United States

Founded in 1986

Phone:

203-798-9988

Fax:

203-791-6234

Key Executives for Boehringer Ingelheim Corporation

Chief Executive Officer and President
Senior Vice President
Age: 58
Public Relations Manager
Chairman of the Board of Managing Directors
Vice President of Sales and Marketing
Compensation as of Fiscal Year 2014.

Boehringer Ingelheim Corporation Key Developments

Boehringer and Eli Lilly Revise Operational Structure of Diabetes Alliance

Boehringer Ingelheim and Eli Lilly and Company have announced that they are revising the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90% of the alliance's anticipated market opportunity will continue their co-promotion work. In all other countries, the companies will exclusively commercialize the respective molecules they brought to the alliance. The changes will be implemented starting January 1, 2015. The scope of the alliance will remain unchanged in the following 17 countries: US, Germany, Italy, Spain, France, UK, Republic of Ireland, Portugal, Canada, Japan, China, Australia, New Zealand, South Korea, Taiwan, Brazil, and Mexico. Under a revised agreement, Boehringer Ingelheim and Lilly will exclusively commercialize the respective molecules they brought to the alliance in all other countries under revised financial terms that will include an upfront payment and ongoing payments paid to Lilly in lieu of commission payments in those markets.

Boehringer Ingelheim Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 02:45 PM

Boehringer Ingelheim Corporation Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 02:45 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Imran Nasrullah, Director, Innovation Sourcing.

Similar Private Companies By Industry

Company Name Region
Perrigo Company Of South Carolina, Inc. United States
Eurand Pharmaceuticals Inc. United States
NeoRx Manufacturing Group, Inc. United States
Medique Products Inc. United States
VGX Animal Health, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boehringer Ingelheim Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.